Valuation: Tenax Therapeutics, Inc.

Market Cap 756M 664M 617M 568M 1.06B 72.97B 1.08B 7.37B 2.88B 35.71B 2.84B 2.78B 124B P/E 2026 *
-10.5x
P/E 2027 * -10.7x
Enterprise Value 156M 137M 127M 117M 219M 15.03B 223M 1.52B 592M 7.35B 584M 572M 25.49B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day-1.01%
1 week-4.56%
Current month+0.62%
1 month+19.51%
3 months+5.17%
6 months-0.95%
Current year+20.10%
1 week 14
Extreme 14
16.26
1 month 12.41
Extreme 12.41
19.4
Current year 10.25
Extreme 10.25
19.4
1 year 5.78
Extreme 5.78
19.4
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,135.04
10 years 2.77
Extreme 2.77
85,120
Manager TitleAgeSince
Chief Executive Officer 52 2021-07-13
Director of Finance/CFO 58 2026-05-10
Chief Tech/Sci/R&D Officer - 2025-01-20
Director TitleAgeSince
Chairman 67 2021-05-31
Director/Board Member 76 2021-02-24
Director/Board Member 69 2021-02-24
Date Insider Type Main position Quantity % Market Cap.
7/13/26 Fiscal year

Chief Executive Officer

17,438 0.0657%
5/11/26 Free

Chief Financial Officer

460,000 2.6748%
5/11/26 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%-4.56%+143.19%-42.81% 756M
+1.08%-6.74%-2.31%+10.45% 46.06B
+3.13%+2.34%+393.21%+605.08% 38.91B
+2.14%+4.98%+10.55%+65.45% 35.57B
+4.43%+0.25%+10.64%-9.17% 33.13B
+1.23%-1.99%-0.05%+30.76% 26.42B
+0.29%-5.92% - - 16.61B
+14.71%+14.47%+26.81%+146.99% 15.08B
-6.32%-4.59%+4.36%+8.22% 14.08B
+1.82%-1.02%+5.46%-30.74% 12.81B
Average +1.92%-2.27%+65.76%+87.14% 23.94B
Weighted average by Cap. +2.09%-2.47%+74.34%+129.12%

Financials

2026 *2027 *
Net sales - -
Net income -79.71M -70.06M -65.1M -59.87M -112M -7.7B -114M -777M -303M -3.77B -299M -293M -13.05B -93.97M -82.6M -76.74M -70.58M -132M -9.07B -135M -916M -358M -4.44B -353M -345M -15.39B
Net Debt -600M -527M -490M -451M -845M -57.94B -861M -5.85B -2.28B -28.35B -2.25B -2.2B -98.26B -
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
26-07-23 US$14.64 -1.01% 1,400,561
26-07-22 US$14.79 -5.92% 1,644,589
26-07-21 US$15.72 +0.26% 1,276,799
26-07-20 US$15.68 -1.07% 823,154
26-07-17 US$15.85 +5.11% 808,315
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.79USD
Average target price
35.22USD
Spread / Average Target
+138.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock